Business
5N Plus Acquires Stake in Microbion and Secures Drug Substance Manufacturing Rights
5N Plus Acquires Stake in Microbion and Secures Drug Substance Manufacturing Rights ...
About this update from 5n Plus Inc.
[{"type":"text","content":"\n \n \n \n 5N Plus Acquires Stake in Microbion and Secures Drug Substance Manufacturing Rights\n \n \n /* Style Definitions */\nspan.prnews_span\n{\nfont-size:8pt;\nfont-family:\"Arial\";\ncolor:black;\n}\na.prnews_a\n{\ncolor:blue;\n}\nli.prnews_li\n{\nfont-size:8pt;\nfont-family:\"Arial\";\ncolor:black;\n}\np.prnews_p\n{\nfont-size:0.62em;\nfont-family:\"Arial\";\ncolor:black;\nmargin:0in;\n}\n \n \n \n \n \n \n Canada NewsWire\n \n \n \n \n \n MONTREAL\n \n and\n \n BOZEMAN, Mont.\n \n ,\n \n Jan. 12, 2021\n \n /CNW/ - 5N Plus Inc. (\"5N Plus\"), a leading global producer of specialty chemicals and engineered materials, and Microbion Corporation (\"Microbion\"), a clinical-stage pharmaceutical company focused on the development of compounds for the treatment of resistant and difficult-to-treat infections, jointly announced today that the parties have entered into a strategic relationship for the development, manufacturing and commercial drug substance supply of Microbion's new class of antibiotic and antibiofilm drugs. Under the terms of the agreement, 5N Plus has taken an equity stake in Microbion and will assume responsibility for the manufacturing of Bismuth-based Active Pharmaceutical Ingredients (API) required in Microbion's family of drug products currently under development, including the company's lead API, pravibismane. Microbion retains responsibility for the development, manufacturing and commercialization of the final drug products currently under development.\n \n \n In recent years, effective treatments for bacterial infections have become ever more critical, as some bacteria have become increasingly resistant to existing drug therapies. Microbion's approach has been to develop a new class of microbial bioenergetic inhibitors that arrest the activities of a broad range of offending pathogens. Pravibismane, the first in this new class of anti-infectives, has demonstrated impressive antibacterial and antibiofilm activity against a wide range of Gram-negative and Gram-positive pathogens, including multiple priority pathogens or \"superbugs\" as identified by the US Centers for Disease Control and Prevention (CDC). As the world's leading producer of Bismuth-based API compounds, 5N Plus is uniquely positioned to support Microbion in the development of this new class of compound. In the initial phase of the...